Methylphenidate Improves Objective QbTest Performance in Adults With ADHD and Polysubstance Use

A single 20-milligram dose of immediate-release methylphenidate produced significant acute improvements across objective measures of attention, motor activity, and impulse control in adults diagnosed with untreated attention-deficit/hyperactivity disorder and concurrent longstanding polysubstance use. In a randomized, double-blind, placebo-controlled crossover study published in BMC Psychiatry, researchers observed marked cognitive gains on standardized objective testing eighty minutes after administering the active medication compared to baseline evaluations, with the therapeutic advantages persisting even after adjusting for measured placebo responses.

Although methylphenidate is a first-line treatment for adult attention-deficit/hyperactivity disorder in Europe, evidence in individuals with co-occurring attention-deficit/hyperactivity disorder and substance use disorder remains limited. Evidence is particularly limited in individuals with longstanding polysubstance use.

To evaluate these cognitive effects under controlled conditions, investigators Monica Löhman, Blanca Domingo, and Lennart Jansson enrolled 39 adult participants with untreated ADHD and extensive polysubstance use histories into a rigorous crossover protocol registered under ClinicalTrials.gov identifier NCT02477280. Each participant completed the computerized QbTest assessment twice per visit: first at baseline and again eighty minutes after receiving either a single 20-milligram capsule of immediate-release methylphenidate or a matched placebo.

The study prioritized three cardinal objective parameters generated by the QbTest apparatus: QbInattention, QbActivity, and QbImpulsivity. Following the administration of immediate-release methylphenidate, participants exhibited statistically significant gains relative to baseline across every cardinal metric. Specifically, QbInattention improved by a mean difference of 1.00 with a 95% confidence interval spanning 0.55 to 1.45, QbActivity improved by a mean difference of 0.83 with a 95% confidence interval from 0.37 to 1.28, and QbImpulsivity improved by a mean difference of 0.83 with a 95% confidence interval of 0.12 to 1.55, with all three objective improvements demonstrating statistical significance at p values below 0.001.

The trial’s double-blind crossover design enabled a precise comparison against placebo administration, which yielded a fundamentally divergent response profile. While methylphenidate demonstrated robust efficacy across inattention, hyperactivity, and impulsivity indices after controlling for inactive capsule effects, placebo administration produced a statistically significant improvement in only a single objective metric: response speed.

In addition to computerized task metrics, the research team systematically gathered subjective self-reports, recording participants’ expected performance, perceived performance, perceived mental effort, perceived benefit from the study medication, and task comprehension. Self-rated expected performance and perceived performance scores increased significantly following immediate-release methylphenidate administration but showed no comparable advancement under placebo conditions. Participants also reported experiencing significantly greater perceived therapeutic benefit from the active drug than from the control capsule, whereas self-rated mental effort declined following both active medication and placebo sessions.

Methodological verification confirmed that task order did not influence the findings, with repeated-measures analyses of variance and paired-samples t-tests detecting no significant QbTest sequence effects across testing days. The authors concluded that immediate-release methylphenidate provides rapid, quantifiable improvements in objective cognitive functioning among clinically challenging adults managing ADHD alongside polysubstance dependencies. Because placebo effects were predominantly confined to subjective perceptions and reaction speed rather than objective self-regulation, the study demonstrates the necessity of integrating objective performance metrics with patient self-reports when appraising initial pharmacological response in complex psychiatric settings.

Subject of Research: Acute cognitive effects of immediate-release methylphenidate in adults with ADHD and longstanding polysubstance use

Article Title: Acute effects of immediate-release methylphenidate on QbTest performance in adults with untreated ADHD and longstanding polysubstance use: a randomized double-blind placebo-controlled crossover study

Article References: Löhman, M., Domingo, B., & Jansson, L. (2026). Acute effects of immediate-release methylphenidate on QbTest performance in adults with untreated ADHD and longstanding polysubstance use: a randomized double-blind placebo-controlled crossover study. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08717-3

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08717-3

Keywords: immediate-release methylphenidate, attention-deficit/hyperactivity disorder, adult ADHD, polysubstance use, substance use disorder, QbTest, QbInattention, QbActivity, QbImpulsivity, crossover study, randomized double-blind trial, placebo comparison, reaction time, objective assessment, subjective outcomes, perceived mental effort, task comprehension, NCT02477280